Uterine Fibroids Market Research Report Information By Type (Intramural Fibroids, Submucosal Fibroids, Subserosal Fibroids, and Others), By Diagnosis (Computed Tomography (CT), Ultrasounds, Medical Resonance Imaging (MRI) Scanners, and Others), By Treatment (Magnetic Resonance Guided Focused Ultrasound, Myolysis, Uterine Fibroid Embolization, Endometrial Ablation, Hysterectomy, and Myomectomy) And By Region (North America, Europe, Asia-Pacific, And Rest Of The World) –Market Forecast Till 2032

Global Uterine Fibroid Market Overview

The Uterine Fibroid Market size was valued at USD 4.2 billion in 2023 and is projected to grow from USD 4.53 Billion in 2024 to USD 8.09 billion by 2032, exhibiting a compound annual growth rate (CAGR) of 7.9% during the forecast period (2024 - 2032). The rise in government awareness programs about the disease, the advancement in the availability of efficient and creative therapies and the high purchasing power of women, and the advancement in the research and development activities are the key market drivers enhancing the market growth.

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

The market is anticipated to be driven by the high prevalence of uterine fibroids among women worldwide, the growing preference of patients for minimally invasive procedures, and the adoption of technologically advanced products. Symptoms of uterine fibroid (UF) include excessive menstrual flow, pelvic pain, infertility, and frequent urination. UF is a benign tumor of the smooth muscle cells of the uterus. Even though the cause is unknown, risk factors include race, age, genetic susceptibility, premenopausal status, hypertension, obesity, and diet.

The increase in government awareness programs regarding the disease, the development of more effective and innovative therapies, the high purchasing power of women, and the development of research and development activities are the main market drivers boosting market growth.

In addition, an increase in patients' preference for minimally invasive and non-invasive fibroids surgeries is anticipated to stimulate market expansion. Smaller incisions reduce post-operative agony and expedite recovery, resulting in widespread adoption of these procedures. Several major players are investing in R&D for the introduction of innovative minimally invasive and non-invasive surgical instruments.

In this procedure, the device emits ultrasound beams, thereby searing and removing targeted tissue from the uterine cavity. This is a non-invasive treatment with minimal to no adverse effects, and patients can resume their normal activities within a few days. Thus, the increasing demand for these techniques, which have a lower risk of infection, minimal discomfort, greater efficacy, and a quicker recovery time than open surgeries, is anticipated to boost the uterine fibroids market.

The market for uterine fibroids treatment devices is anticipated to increase as a result of the growing demand for minimally invasive procedures due to their relative lack of discomfort, efficacy, low risk of infection, and speedy recovery compared to open surgery. In addition to expanding uterine fibroids awareness and education beyond gynecologic clinicians, promoting individualized patient treatment through collaborative decision-making was also identified as a means of addressing unmet needs.

In January 2024, Pfizer Canada ULC announced that MYFEMBREE is now available for prescription in Canada to treat heavy menstrual bleeding due to fibroids and endometriosis-related pain.

Gynesonics received a significant USD 42.5 million investment in November 2023 for the commercialization of its innovative uterine fibroids device. Gynesonics is devoted to progressing non-surgical minimally invasive technology both for diagnosis and therapy purposes.

For example, the US Food and Drug Administration approved Nesa Medtech’s fibroid mapping tool as Femtech did in July 2023. Diagnosing uterine fibroids and guiding interventional procedures are the goals of its Fibroid Mapping Reviewer Application by patients with uterine fibroids who undergo ultrasound scans that generate three-dimensional models of their uterus that reveal their size.

Nesa Medtech was cleared by the United States Food and Drug Administration (FDA) in July 2023 to provide a review application called the Fibroid Mapping Reviewer Application (FMRA). It is an advanced piece of software that allows physicians to build detailed three-dimensional models of the uterus using data from ultrasound images. These models are vital when it comes to accurate diagnoses as well as facilitating the planning of intervention strategies for women with uterine fibroids.

For instance, Ryeqo by Gedeon Richter Australia Pty Ltd has been approved in August 2022 by the Therapeutic Goods Administration (TGA) for treatment of moderate to severe symptoms of uterine fibroids among adult women capable of reproduction aged above eighteen years old.

The UK Medicines and The Healthcare Products Regulatory Agency (MHRA) have authorized Yselty—an oral GnRH antagonist—for use in treating mild through extreme indications associated with reproductive years’ symptomatic uterine fibroids (UF). ObsEva SA is a biopharmaceutical firm engaged in development and commercialization of unique healthcare products primarily for women.

In November 2022, India Medtronic Private Limited introduced the TruClear system, which is a mechanically operated hysteroscopic tissue removal tool that safely and efficiently treats intrauterine abnormalities (IUA). IUA is commonly used to diagnose conditions such as fibroids, polyps, adhesions, cancer, hyperplasia and retained products of conception.

June 2022: ObsEva SA, a biopharmaceutical company developing and commercializing novel therapies for women's health, announced in June 2022 that the European Commission (EC) has granted marketing authorization for Yselty® (linzagolix), an oral GnRH antagonist, for the management of moderate to severe symptoms of uterine fibroids (UF) in adult women (over 18 years of age) of reproductive age. Yselty® is the only FDA-approved oral GnRH antagonist that offers women with UF flexible dosing alternatives with and without supplemental hormonal therapy.

Uterine Fibroid Market Trends

• The rising number of hysterectomies is driving the market growth

Market CAGR for uterine fibroid is driven by the rising number of hysterectomy surgical procedures. This method is the most popular and well-proven permanent treatment for uterine fibroids. As a result, the hysterectomy will likely grow as the number of related surgeries increases. For instance, in November 2020, as per the article issued in the Journal of Gynecologic Oncology, by the Centers for Disease Control and Prevention, approximately 600,000 hysterectomies are completed in the US every year. For instance, in November 2022, as per the American College of Obstetricians and Gynecologists, around a third of all women will have a hysterectomy by age 60.

Moreover, an expansion in patients' preference for minimally and non-invasive fibroids surgeries is expected to boost market growth. Smaller incisions reduce post-operative pain and facilitate speedy recovery, thus showing to high adoption of these techniques. Several key participants are investing in R&D for the launch of creative minimally and non-invasive surgical instruments. For instance, the MR-guided Focused Ultrasound (MRgFUS) utilized for treating uterine fibroids is one of the incision techniques physicians widely recommend. The device delivers ultrasound beams in this technique, thus heating and withdrawing targeted tissue from the uterine cavity. This is a non-invasive treatment with slight to no side consequences, and patients may return to regular activity within a few days. Thus, the growing demand for such techniques due to less chance of infection, minimal pain, efficacy, and speedy recovery compared to open surgeries is expected to boost the demand for the uterine fibroids market.

Additionally, an expansion in the number of cases of uterine fibroids-related disorders in developed and developing economies has driven the launch of technologically developed products in the market. For instance, Channel Medsystem's Cerene Cryotherapy device treats heavy bleeding. This device utilizes extreme cold to eliminate the lining of the uterus tissues to relieve heavy menstrual bleeding without providing general anesthesia. In addition, Insightec's MR-guided Focused Ultrasound (MRgFUS) is utilized to treat uterine fibroids. This incision-less procedure delivers ultrasound beams, thus heating and removing targeted tissue from the uterine. Thus, market players are making constant efforts to introduce technologically advanced products in the market.

In addition to developing new treatments, there is a growing emphasis on raising awareness of uterine fibroids and educating individuals about the condition. This includes efforts by companies. For instance, in November 2021, Minerva Surgical launched a uterine health education website all over the globe. Combining new treatments and increased awareness of uterine fibroids is expected to drive significant market growth as more individuals seek effective treatment options for this condition, driving the revenue of the uterine fibroid market.

Uterine Fibroid Market Segment Insights

Uterine Fibroid Type Insights

The uterine fibroid market segmentation, based on type, includes subserosal fibroids, intramural fibroids, submucosal fibroids, and others. The submucosal fibroids segment dominated the market, accounting for 35% of market revenue (0.07 Billion). In developing economies, category growth is driven as this type of fibroid develops in the muscle layer of the uterus, underneath the inner lining, & grows into the uterine cavity. However, intramural fibroids are the fastest-growing category as they significantly reduce fertility outcomes, making treatment necessary.

Uterine Fibroid Diagnosis Insights

The uterine fibroid market segmentation, based on diagnosis, includes medical resonance imaging (MRI) scanners, computed tomography (CT), ultrasounds, and others. The computed tomography (CT) category generated the most income (70.4%) as this technology improves diagnoses, prevents unnecessary medical procedures, improves treatment by providing detailed anatomical imaging, and is a cost-effective imaging technique. However, computed tomography (CT) is the fastest-growing category due to the development of a high-precision CT scanner by integrating AI & ML and advanced visualization systems.

Uterine Fibroid Treatment Insights

The uterine fibroid market segmentation, based on treatment, includes uterine fibroid embolization, magnetic resonance-guided focused ultrasound, myolysis, endometrial ablation, hysterectomy, and myomectomy. The hysterectomy category generated the most income due to the rising number of hysterectomy surgical procedures. However, myomectomy is the fastest-growing category as it eliminates fibroids, preserves the uterus, and allows patients to remain fertile.

Figure 1 Uterine Fibroid Market, by Treatment, 2023 & 2032 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Uterine Fibroid Regional Insights

By region, the study provides market insights into North America, Europe, Asia-Pacific and the Rest of the World. The North American uterine fibroid market will dominate this market. The rising prevalence of uterine fibroids, increasing pregnancy complications due to fibroids, and the approval of novel treatment options will boost the market growth in this region. Further, the US uterine fibroid market held the largest market share, and the Canadian uterine fibroid market was the fastest-growing market in the North American region.

Further, the prominent countries studied in the market report are The US, Canada, German, France, the UK, Italy, Spain, China, Japan, India, Australia, South Korea, and Brazil.

June 2022: The U.S. Food and Drug Administration (FDA) has accepted for review a supplemental New Drug Application (sNDA) for MYFEMBREE (relugolix 40 mg, estradiol 1 mg, and norethydrone acetate 0.5 mg) submitted by Myovant Sciences and Pfizer Inc. in June 2022. The sNDA proposes modifications to the United States Prescribing Information (USPI) for MYFEMBREE based on safety and efficacy data from the Phase 3 LIBERTY randomized withdrawal study (RWS) of MYFEMBREE in premenopausal women with excessive menstrual hemorrhage associated with uterine fibroids for up to two years.

Figure 2 UTERINE FIBROID MARKET SHARE BY REGION 2023 (USD Billion)

Source Secondary Research, Primary Research, MRFR Database and Analyst Review

Europe's uterine fibroid market accounts for the second-largest market share due to the existence of well-established healthcare facilities in the region, increased government initiatives, and an increase in hysterectomy-related surgical procedures/hospital visits drive the market in this region. Further, the German uterine fibroid market held the largest market share, and the UK uterine fibroid market was the fastest-growing market in the European region.

The Asia-Pacific uterine fibroid market is expected to grow at the fastest CAGR from 2024 to 2032. This is owing to growing awareness about the availability of novel treatment options, and the increasing adoption of minimally invasive surgeries will boost market growth in this region. Moreover, China’s uterine fibroid market held the largest market share, and the Indian uterine fibroid market was the fastest-growing market in the Asia-Pacific region.

Uterine Fibroid Key Market Players & Competitive Insights

Leading market participants are investing heavily in research and development to extend their product lines, which will allow the uterine fibroid market to grow even more. Market participants are also undertaking different strategic activities to extend their  footprint, with important market developments including contractual agreements, mergers and acquisitions, new product launches, higher investments, and collaboration with other firms. To extend and survive in a more competitive and growing market climate, the uterine fibroid industry must deliver cost-effective items.

Manufacturing locally to decrease operational costs is one of the major business tactics manufacturers utilize in the  uterine fibroid industry to benefit clients and increase the market sector. Major players in the uterine fibroid market, including GlaxoSmithKline plc, F. Hoffmann-La Roche Ltd, Pfizer Inc, Novartis AG, Bristol-Myers Squibb Company, and others, are attempting to enhance market demand by investing in research and development operations.

Pfizer Inc discovers, develops, manufactures, and commercializes biopharmaceuticals. The firm offers products to treat numerous conditions such as cardiovascular, women's health, cancer, inflammation, metabolic and pain, immune disorders, and rare diseases. It also delivers biosimilars, sterile injectable pharmaceuticals, active pharmaceutical ingredients and contract manufacturing services. Pfizer markets its products through wholesalers, retailers, hospitals, individual provider offices, clinics, government agencies and pharmacies. It has major manufacturing facilities worldwide. In February 2021, Pfizer and Myovant released favorable results from the Phase III LIBERTY 1 and LIBERTY 2 investigations. In women with uterine fibroids, the companies are testing a once-daily combination therapy of relugolix plus estradiol and norethindrone acetate.

Olympus Corp is a firm that produces precise machinery and tools for optics and digital technology. The firm develops, manufactures and commercializes equipment and devices for medical, imaging, information, healthcare, and other industrial markets. It delivers medical systems, such as endotherapy devices, endoscopes and endoscopy products to support healthcare professionals in treating patients, and scientific solutions, such as laser scanning microscopes, industrial and biological microscope systems, remote visual inspection products and non-destructive testing systems. It also delivers biomedical materials and system development services. In November 2022, Olympus Corporation, a  technology in developing and providing creative solutions for medical and surgical techniques, announced the market establish of the resolution Power Morcellator, which is manufactured by TROKAMED GmbH and is available in the U.S. via a distribution agreement with Olympus America, Inc. The resolution Morcellator is designed for advanced gynecologic procedures with large, calcified tissue specimens.

 Key Companies in the Uterine Fibroids market include

• GlaxoSmithKline plc


• Hoffmann-La Roche Ltd


• Pfizer Inc


• Novartis AG


• Bristol-Myers Squibb Company


• Sanofi


• Teva Pharmaceutical Industries Ltd.


• Amgen Inc, Medtronic


• Endo International plc


• Mylan N.V


• Sun Pharmaceutical Industries Ltd


• Hologic, Inc


• Smith & Nephew


• Merck & Co., Inc,

Uterine Fibroid Industry Developments

September 2021 Kissei Pharma agreed with Bio Genuine to develop & commercialize "linzagolix" in China.

May 2021 Myovant Sciences and Pfizer Inc. announced that the United States Food and Drug Administration had approved MYFEMBREE, the first once-daily treatment for controlling heavy menstrual bleeding associated with uterine fibroids in premenopausal women, with a therapy period of up to 24 months.

Uterine Fibroid Market Segmentation

Uterine Fibroid Type Outlook

• Subserosal Fibroids


• Intramural Fibroids


• Submucosal Fibroids


• Others

Uterine Fibroid Diagnosis Outlook

• Medical Resonance Imaging (MRI) Scanners


• Computed Tomography (CT)


• Ultrasounds


• Others

Uterine Fibroid Treatment Outlook

• Uterine Fibroid Embolization


• Magnetic Resonance Guided Focused Ultrasound


• Myolysis


• Endometrial Ablation


• Hysterectomy


• Myomectomy

Uterine Fibroid Regional Outlook

• North America
  
  
  
  • US
  
  
  • Canada
  
  
  
  


• Europe
  
  
  
  • Germany
  
  
  • France
  
  
  • UK
  
  
  • Italy
  
  
  • Spain
  
  
  • Rest of Europe
  
  
  
  


• Asia-Pacific
  
  
  
  • China
  
  
  • Japan
  
  
  • India
  
  
  • Australia
  
  
  • South Korea
  
  
  • Australia
  
  
  • Rest of Asia-Pacific
  
  
  
  


• Rest of the World
  
  
  
  • Middle East
  
  
  • Africa
  
  
  • Latin America